3rd Retinal Imaging Biomarkers and Endpoints Summit

Start: Tuesday, May 27, 2025 8:00AM
End: Thursday, May 29, 2025 5:00PM

Accelerate Your Ophthalmic Development with Deep Learning Systems and Sophisticated AI Imaging Technologies...

With state-of-the-art AI-assisted technology making retinal imaging 100 times faster, the rapid advancement of technology in ophthalmology, coupled with the strong unmet need for more drugs for retinal diseases, highlights the urgency of continued focus and progress in this space. This need is emphasized by Merck's recent $3 billion acquisition of EyeBio. In light of this, as we move into 2025 and beyond, there is a real need to re-unite the retinal imaging biomarkers and endpoints community to align efforts and propel the field to new heights.

The 3rd Annual Retinal Imaging Biomarkers and Endpoints Summit is addressing this need head on by uniting clinical scientists, imaging scientists, medical directors, R AND D, imaging technology and algorithm engineers once again. They will be sharing case studies and real-world examples of how retinal imaging biomarkers and endpoints are impacting clinical trials, that ultimately save pharma and biotech both time and money, two of the largest challenges facing drug developers in the pivotal work they do.

This event is the perfect bridge of those developing technology and those using the technology to ensure the efficacious development of endpoints for regulatory approval in retinal diseases such as dry and wet AMD, GA, GR and DME.

URLs:
Tickets: https://go.evvnt.com/2897738-2?pid=3698
Brochure: https://go.evvnt.com/2897738-3?pid=3698

Prices:
Drug Developer Pricing - Conference + Pre-Conference Workshop Day: USD 4197.00,
Drug Developer Pricing - Conference Only: USD 2999.00,
Academic Pricing - Conference + Pre-Conference Workshop Day: USD 3597.00,
Academic Pricing - Conference Only: USD 2599.00,
Solution Provider Pricing - Conference + Pre-Conference Workshop Day: USD 5097.00,
Solution Provider Pricing - Conference Only: USD 3699.00

Speakers: Amitha Domalpally, Assistant Professor and Director, University of Wisconsin-Madison, Archana Nigalye, Associate Director Medical, Alexion, Ash Jayagopal, Chief Scientific and Development Officer, Opus Genetics, Brian Levy, Chief Executive Officer, Ocunexus Therapeutics, Cyril Eleftheriou, Principal Scientist, Novartis, Daniil Gataulin, Senior Analyst, Biotech Equity Research, Chardan Capital Markets, Francesca Cordeiro, Professor of Glaucoma and Retinal Neurodegeneration Studies, University College London - UCL, Laure Blouin, Director - Clinical Science and Medical Communications, SparingVision, Maryam Mokhtarzadeh, Senior Director, Regulatory Strategy, REGENXBIO, Mayssa Attar, Senior Vice President and Head of Pharmaceutical, Consumer Research and Development, Bausch + Lomb, Mohammad Eslami, Instructor, Harvard Medical School, Najam Sharif, Vice President - Global Research and Development, Nanoscope Therapeutics, Shelley Boyd, Chief Executive Officer, Translatum Medicus, Tara DeSilva, Associate Professor, Cleveland Clinic Taussig Cancer Institute, Touseef Qureshi, Assistant Professor, Cedars-Sinai Medical Center, Yaniv Barkana, Chief Medical Officer, Galimedix